Library Logo

Drug repositioning : (Record no. 206061)

000 -LEADER
fixed length control field 07359cam a2200889Ma 4500
001 - CONTROL NUMBER
control field ocn802068199
003 - CONTROL NUMBER IDENTIFIER
control field OCoLC
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20170612141630.0
006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS
fixed length control field m o d
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr |n|||||||||
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 111025s2012 njua ob 001 0 eng d
010 ## - LIBRARY OF CONGRESS CONTROL NUMBER
Canceled/invalid LC control number 2011044253
040 ## - CATALOGING SOURCE
Original cataloging agency CDX
Language of cataloging eng
Description conventions pn
Transcribing agency CDX
Modifying agency OCLCO
-- E7B
-- OCLCQ
-- OSU
-- OCLCQ
-- OCLCF
-- NLGGC
-- DG1
-- CUS
-- OHI
-- RECBK
-- OCLCQ
-- EBLCP
-- N$T
-- YDXCP
-- DEBSZ
-- OCLCQ
-- COO
-- OCLCQ
-- DEBBG
-- AZK
-- LOA
-- OCLCO
-- OCLCA
019 ## -
-- 793103971
-- 795120559
-- 864909734
-- 961530929
-- 962709413
-- 966211549
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9780470878279
Qualifying information (hbk.)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 0470878274
Qualifying information (hbk.)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781118274408
Qualifying information (electronic bk.)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 1118274407
Qualifying information (electronic bk.)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781118274392
Qualifying information (electronic bk.)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 1118274393
Qualifying information (electronic bk.)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781118274378
Qualifying information (electronic bk.)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 1118274377
Qualifying information (electronic bk.)
024 8# - OTHER STANDARD IDENTIFIER
Standard number or code 9786613673718
028 01 - PUBLISHER NUMBER
Publisher number EB00063228
Source Recorded Books
029 1# - OTHER SYSTEM CONTROL NUMBER (OCLC)
OCLC library identifier AU@
System control number 000049595380
029 1# - OTHER SYSTEM CONTROL NUMBER (OCLC)
OCLC library identifier AU@
System control number 000052905589
029 1# - OTHER SYSTEM CONTROL NUMBER (OCLC)
OCLC library identifier DEBSZ
System control number 431150141
029 1# - OTHER SYSTEM CONTROL NUMBER (OCLC)
OCLC library identifier DKDLA
System control number 820120-katalog:000599886
029 1# - OTHER SYSTEM CONTROL NUMBER (OCLC)
OCLC library identifier GBVCP
System control number 790037092
029 1# - OTHER SYSTEM CONTROL NUMBER (OCLC)
OCLC library identifier NLGGC
System control number 35648761X
029 1# - OTHER SYSTEM CONTROL NUMBER (OCLC)
OCLC library identifier NZ1
System control number 14976581
029 1# - OTHER SYSTEM CONTROL NUMBER (OCLC)
OCLC library identifier DEBBG
System control number BV043394928
035 ## - SYSTEM CONTROL NUMBER
System control number (OCoLC)802068199
Canceled/invalid control number (OCoLC)793103971
-- (OCoLC)795120559
-- (OCoLC)864909734
-- (OCoLC)961530929
-- (OCoLC)962709413
-- (OCoLC)966211549
037 ## - SOURCE OF ACQUISITION
Stock number 367371
Source of stock number/acquisition MIL
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number RM301.25
Item number .D78 2012eb
060 #4 - NATIONAL LIBRARY OF MEDICINE CALL NUMBER
Classification number QV 55
072 #7 - SUBJECT CATEGORY CODE
Subject category code BUS
Subject category code subdivision 070130
Source bisacsh
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 338.4/76151
Edition number 23
049 ## - LOCAL HOLDINGS (OCLC)
Holding library MAIN
245 00 - TITLE STATEMENT
Title Drug repositioning :
Remainder of title bringing new life to shelved assets and existing drugs /
Statement of responsibility, etc. edited by Michael J. Barratt, Donald E. Frail.
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT)
Place of publication, distribution, etc. Hoboken, N.J. :
Name of publisher, distributor, etc. Wiley,
Date of publication, distribution, etc. ©2012.
300 ## - PHYSICAL DESCRIPTION
Extent 1 online resource (xx, 477 pages) :
Other physical details illustrations
336 ## - CONTENT TYPE
Content type term text
Content type code txt
Source rdacontent
337 ## - MEDIA TYPE
Media type term computer
Media type code c
Source rdamedia
338 ## - CARRIER TYPE
Carrier type term online resource
Carrier type code cr
Source rdacarrier
347 ## - DIGITAL FILE CHARACTERISTICS
File type data file
Source rda
380 ## - FORM OF WORK
Form of work Bibliography
504 ## - BIBLIOGRAPHY, ETC. NOTE
Bibliography, etc Includes bibliographical references and index.
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note Drug repositioning : the business case and current strategies to repurpose shelved candidates and marketed drugs / John Arrowsmith and Richard Harrison -- Opportunities and challenges associated with developing additional indications for clinical development candidates and marketed drugs / Donald E. Frail and Michael J. Barratt -- Clinical and operational considerations in repositioning marketed drugs and drug candidates / Damian O'Connell, David J. Sequeira, and Maria L. Miller -- Regulatory considerations and strategies for drug repositioning / Ken Phelps -- Computational and bioinformatic strategies for drug repositioning / Richard Mazzarella and Craig Webb -- Mining scientific and clinical databases to identify novel uses for existing drugs / Christos Andronis [and others] -- Predicting the polypharmacology of drugs : identifying new uses through chemoinformatics, structural informatics, and molecular modeling-based approaches / Li Xie [and others] -- Systematic phenotypic screening for novel synergistic combinations: a new paradigm for repositioning existing drugs / Margaret S. Lee -- Phenotypic in vivo screening to identify new, unpredicted indications for existing drugs and drug candidates / Michael S. Saporito, Christopher A. Lipinski, and Andrew G. Reaume -- Old drugs yield new discoveries : examples from the prodrug, chiral switch and site-selective deuteration strategies / Adam J. Morgan [and others] -- Repurposing drugs for tropical diseases : case studies and open-source screening initiatives / Curtis R. Chong -- Drug repositioning efforts by nonprofit foundations -- Business development strategies in the repositioning industry / Aris Persidis and Elizabeth T. Stark -- A case study in drug repositioning : Sosei / Akinori Mochizuki and Makiko Aoyama.
588 ## - SOURCE OF DESCRIPTION NOTE
Source of description note Print version record.
520 ## - SUMMARY, ETC.
Summary, etc. BThe how's and why's of successful drug repositioning /b/ Drug repositioning, also known as drug reprofiling or repurposing, has become an increasingly important part of the drug development process. This book examines the business, technical, scientific, and operational challenges and opportunities that drug repositioning offers. Readers will learn how to perform the latest experimental and computational methods that support drug repositioning, and detailed case studies throughout the book demonstrate how these methods fit within the context of a comprehensive drug repositioning strategy./ iDrug Repositioning/i is divided into three parts:/ ulli bPart 1, Drug Repositioning: Business Case, Strategies, and Operational Considerations, /b examines the medical and commercial drivers underpinning the quest to reposition existing drugs, guiding readers through the key strategic, technical, operational, and regulatory decisions needed for successful drug repositioning programs./ /lili bPart 2, Application of Technology Platforms to Uncover New Indications and Repurpose Existing Drugs, /b sets forth computational-based strategies, tools, and databases that have been designed for repositioning studies, screening approaches, including combinations of existing drugs, and a look at the development of chemically modified analogs of approved agents./ /lili bPart 3, Academic and Non-Profit Initiatives & the Role of Alliances in the Drug Repositioning Industry/b, explores current investigations for repositioning drugs to treat rare and neglected diseases, which are frequently overlooked by for-profit pharmaceutical companies due to their lack of commercial return./ /li/ul The book's appendix provides valuable resources for drug repositioning researchers, including information on drug repositioning and reformulation companies, databases, government resources and organizations, regulatory agencies, and drug repositioning initiatives from academia and non-profits./ With this book as their guide, students and pharmaceutical researchers can learn how to use drug repositioning techniques to extend the lifespan and applications of existing drugs as well as maximize the return on investment in drug research and development.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Drug development.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Pharmaceutical industry.
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Drug Repositioning.
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Computational Biology
General subdivision methods.
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Drug Industry
General subdivision economics.
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Pharmaceutical Preparations
General subdivision economics.
650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Medical.
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element MEDICAL
General subdivision Pharmacology.
Source of heading or term bisacsh
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Drug development.
Source of heading or term fast
Authority record control number (OCoLC)fst00898670
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Pharmaceutical industry.
Source of heading or term fast
Authority record control number (OCoLC)fst01060129
655 #4 - INDEX TERM--GENRE/FORM
Genre/form data or focus term Electronic books.
655 #7 - INDEX TERM--GENRE/FORM
Genre/form data or focus term Electronic books.
Source of term local
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Barratt, Michael J.
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Frail, Donald.
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Relationship information Print version:
International Standard Book Number 9786613673718
Record control number (OCoLC)758943206
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier http://onlinelibrary.wiley.com/book/10.1002/9781118274408
Public note Wiley Online Library
938 ## -
-- Coutts Information Services
-- COUT
-- 22634737
938 ## -
-- EBL - Ebook Library
-- EBLB
-- EBL938848
938 ## -
-- ebrary
-- EBRY
-- ebr10580300
938 ## -
-- EBSCOhost
-- EBSC
-- 462265
938 ## -
-- Recorded Books, LLC
-- RECE
-- rbeEB00063228
938 ## -
-- YBP Library Services
-- YANK
-- 8856204
938 ## -
-- YBP Library Services
-- YANK
-- 7700762
938 ## -
-- YBP Library Services
-- YANK
-- 12671679
994 ## -
-- 92
-- DG1

No items available.

Last Updated on September 15, 2019
© Dhaka University Library. All Rights Reserved|Staff Login